PIA
PACB icon

Piedmont Investment Advisors’s Pacific Biosciences PACB Stock Holding History

Piedmont Investment Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,115
Closed -$8K – 1911
2018
Q2 		$8K Buy
+2,115
New +$5.87K ﹤0.01% 1924

Other funds holding PACB

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Piedmont Investment Advisors's PACB Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Pacific Biosciences (PACB) in Q3 2018, closing a stake of 2,115 shares — an estimated $8K sold.

Piedmont Investment Advisors first reported a position in PACB in Q2 2018 and held it in 1 quarter. The position peaked at $8K in Q2 2018. 118 funds tracked by Wall St. Rank hold PACB as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Pacific Biosciences position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 2,115 Pacific Biosciences shares in Q3 2018, an estimated $8K.
  • Piedmont Investment Advisors first reported a position in Pacific Biosciences in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Pacific Biosciences position peaked at $8K in Q2 2018.
  • 118 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.